Answers are grounded in this paper and cite their sources.
Fixed-dose combination therapy (the polypill) was first proposed for cardiovascular prevention over two decades ago.1 While fixed-dose combination therapy has long been accepted in the treatment of HIV and tuberculosis, adoption has been slow for cardiovascular prevention. Evidence favouring polypill strategies has gradually accumulated, the paper by Gaziano et al. in this issue of The Lancet Regional Health–Europe paper is a useful addition to the evidence.2
No takes yet. Share an insight, caveat, or question.
Tom Marshall (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: